Meeting NewsVideo

VIDEO: Pediatric cholestatic disease therapy improves bile acids, reduces pruritus

VIENNA — In this exclusive video from the International Liver Congress 2019, Patrick T. Horn, MD, PhD, chief medical officer of Albireo Pharmaceuticals, provides an update on A4250, an ileal bile acid transporter inhibitor for the treatment of pediatric cholestatic diseases.

“Albireo has the potential to bring forward some products that can be life-altering for these patients with pediatric cholestatic disease,” Horn told Healio Gastroenterology and Liver Disease. “Across the spectrum of pediatric cholestatic liver diseases, A4250 is able to lower bile acids and show symptomatic improvements.”

At the meeting, researchers presented data from a phase 2 study of A4250 in pediatric patients with biliary atresia and a phase 2 study of pediatric patients with Alagille syndrome. In both studies, A4250 was well-tolerated and showed significant improvements in bile acids and reductions in pruritus.

Horn also noted that Albireo has a phase 3 program ongoing to evaluate A4250 for progressive familial intrahepatic cholestasis.

Reference:

Baumann U. Abstract FRI-060. Presented at: International Liver Congress; April 10-14, 2019; Vienna, Austria.

Sturm E. Abstract FRI-060. Presented at: International Liver Congress; April 10-14, 2019; Vienna, Austria.

Disclosure: Horn is the chief medical officer of Albireo Pharmaceuticals.

VIENNA — In this exclusive video from the International Liver Congress 2019, Patrick T. Horn, MD, PhD, chief medical officer of Albireo Pharmaceuticals, provides an update on A4250, an ileal bile acid transporter inhibitor for the treatment of pediatric cholestatic diseases.

“Albireo has the potential to bring forward some products that can be life-altering for these patients with pediatric cholestatic disease,” Horn told Healio Gastroenterology and Liver Disease. “Across the spectrum of pediatric cholestatic liver diseases, A4250 is able to lower bile acids and show symptomatic improvements.”

At the meeting, researchers presented data from a phase 2 study of A4250 in pediatric patients with biliary atresia and a phase 2 study of pediatric patients with Alagille syndrome. In both studies, A4250 was well-tolerated and showed significant improvements in bile acids and reductions in pruritus.

Horn also noted that Albireo has a phase 3 program ongoing to evaluate A4250 for progressive familial intrahepatic cholestasis.

Reference:

Baumann U. Abstract FRI-060. Presented at: International Liver Congress; April 10-14, 2019; Vienna, Austria.

Sturm E. Abstract FRI-060. Presented at: International Liver Congress; April 10-14, 2019; Vienna, Austria.

Disclosure: Horn is the chief medical officer of Albireo Pharmaceuticals.

    See more from International Liver Congress